X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
SkQ1 (visomitin), is a cardiolipin peroxidation inhibitor, designed to sustain and restore mitochondrial function and interrupt apoptosis in mitochondrial conditions like LHON, dry eye disease and glaucoma.
Lead Product(s): Visomitin
Therapeutic Area: Ophthalmology Product Name: SkQ1
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2022
Details:
USFDA has granted ODD for the company’s topical cardiolipin peroxidation inhibitor, SkQ1(Visomitin), for the treatment of Leber’s Hereditary Optic Neuropathy a rare inherited condition that can lead to blindness.
Lead Product(s): Visomitin
Therapeutic Area: Ophthalmology Product Name: SkQ1
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2021
Details:
VISTA-2 is a multi-centre, randomized, double-blind, placebo-controlled clinical study involving two treatment arms: SkQ1 ophthalmic solution and vehicle solution, administered BID.
Lead Product(s): Visomitin
Therapeutic Area: Ophthalmology Product Name: SkQ1
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Essex Bio
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
